Advanced search
Publication Cover
Neurodegenerative Disease Management Volume 9, 2019 - Issue 5
Submit an article Journal homepage
104
Views
0
CrossRef citations to date
0
Altmetric
Commentary

Is Huntington’s Disease On the Threshold of a New Era in Treatment?

Sherry Sandy1 Faculty of Medical Sciences University of the West Indies Charlotte Street Port of SpainTrinidadIndies
&
Alby Richard2 Department of Neurology Faculty of Medicine Centre de Recherche du CHUM (CR-CHUM) University of MontrealMontrealQuebecH2X 0A9CanadaCorrespondence[email protected]
Pages 255-258 | Received 14 Aug 2019, Accepted 22 Aug 2019, Published online: 03 Oct 2019

References

  • Bates GP . The molecular genetics of Huntington disease – a history. Nat. Rev. Genet., 6(10), 766–773 (2005).
  • Pringsheim T , WiltshireK, DayL, DykemanJ, SteevesT, JetteN. The incidence and prevalence of Huntington’s disease: a systematic review and meta-analysis. Mov. Disord., 27(9), 1083–1091 (2012).
  • Burton A . Hope, humanity, and Huntington’s disease in Latin America. Lancet Neurol., 12(2), 133–134 (2013).
  • Frank S . Treatment of Huntington’s disease. Neurotherapeutics, 11(1), 153–160 (2014).
  • Richard A , FrankS. Deutetrabenazine in the treatment of Huntington’s disease. Neurodegener. Dis. Manag., 9(1), 31–37 (2019).
  • Zeitlin S , LiuJP, ChapmanDL, PapaioannouVE, EfstratiadisA. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington’s disease gene homologue. Nat. Genet., 11(2), 155–163 (1995).
  • Liu JP , ZeitlinSO. Is huntingtin dispensable in the adult brain?J. Huntingtons Dis., 6(1), 1–17 (2017).
  • Bates GP , DorseyR, GusellaJFet al. Huntington disease. Nat. Rev. Dis. Prim., 1, 15005 (2015).
  • Angus D , HerdC, StoneCet al. Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: a Phase II, randomised, double-blind, placebo-controlled trial. Lancet Neurol., 14(1), 39–47 (2015).
  • Reilmann R , SquitieriF, PrillerJet al. Safety and tolerability of selisistat for the treatment of Huntington’s disease: results from a randomized, double-blind, placebo-controlled Phase II trial (S47.004). Neurology, 82(Suppl. 10), S47.004 (2014).
  • Kordasiewicz HB , StanekLM, WancewiczEVet al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron, 74(6), 1031–1044 (2012).
  • Stanek LM , SardiSP, MastisBet al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum. Gene Ther., 25(5), 461–474 (2014).
  • Tabrizi SJ , LeavittBR, LandwehrmeyerGBet al. Targeting huntingtin expression in patients with Huntington’s disease. N. Engl. J. Med., 380(24), 2307–2316 (2019).
  • Hersch S , ClaassenD, EdmondsonM, WildE, GuercioliniR, PanzaraM. Multicenter, randomized, double-blind, placebo-controlled Phase Ib/IIa studies of WVE-120101 and WVE-120102 in patients with Huntington’s disease (P2.006). Neurology, 88(Suppl. 16), 2.006 (2017).
  • Wurster CD , LudolphAC. Antisense oligonucleotides in neurological disorders. Ther. Adv. Neurol. Disord., 11, doi:10.1177/1756286418776932 (2018).
  • Finkel RS , MercuriE, DarrasBTet al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med., 377(18), 1723–1732 (2017).
  • Wild EJ , BoggioR, LangbehnDet al. Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J. Clin. Invest., 125(5), 1979–1986 (2015).
  • Wang N , GrayM, LuXHet al. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease. Nat. Med., 20(5), 536–541 (2014).
  • Yamamoto A , LucasJJ, HenR. Reversal of neuropathology and motor dysfunction in a conditional model of Huntington’s disease. Cell, 101(1), 57–66 (2000).
  • Pallos J , BodaiL, LukacsovichTet al. Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington’s disease. Hum. Mol. Genet., 17(23), 3767–3775 (2008).
  • Nalavade R , GriescheN, RyanDP, HildebrandS, KraußS. Mechanisms of RNA-induced toxicity in CAG repeat disorders. Cell Death Dis., 4, e752 (2013).
  • Fink KD , DengP, GutierrezJet al. Allele-specific reduction of the mutant huntingtin allele using transcription activator-like effectors in human Huntington’s disease fibroblasts. Cell Transplant., 25(4), 677–686 (2016).
  • Shin JW , KimK-H, ChaoMJet al. Permanent inactivation of Huntington’s disease mutation by personalized allele-specific CRISPR/Cas9. Hum. Mol. Genet., 25(20), 4566–4576 (2016).
  • Monteys AM , EbanksSA, KeiserMS, DavidsonBL. CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol. Ther., 25(1), 12–23 (2017).
  • Heman-Ackah SM , BassettAR, WoodMJA. Precision modulation of neurodegenerative disease-related gene expression in human iPSC-derived neurons. Sci. Rep., 6, 28420 (2016).
  • Ormond KE , MortlockDP, ScholesDTet al. Human germline genome editing. Am. J. Hum. Genet., 101(2), 167–176 (2017).
  • MacDonald ME , AmbroseCM, DuyaoMPet al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell, 72(6), 971–983 (1993).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.